Travere Therapeutics Inc.
TVTX | NASDAQ
$62.86
+$0.10 (+0.16%)
At close: Sep 21, 2026, 4:00 PM ET
$61.12
-$1.74 (-2.77%)
Pre-market:
Sep 22, 2026, 8:46 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -68.23 | -4.27 | -5.99 | -4.81 | -10.31 | -7.66 |
PEG Ratio | 0.79 | -0.02 | 0.09 | -0.11 | 0.67 | -2.65 |
PS Ratio | 6.95 | 5.89 | 4.60 | 12.25 | 14.09 | 6.53 |
PB Ratio | 29.69 | 23.26 | 3.32 | 31.29 | 6.15 | 6.13 |
P/FCF Ratio | -167.32 | -4.06 | -2.08 | -6.25 | -47.69 | -7.97 |
P/OCF Ratio | 90.22 | -5.79 | -2.38 | -7.20 | -125.55 | -30.31 |
OCF/S Ratio | 7.70 | -101.84 | -192.80 | -170.19 | -11.22 | -21.55 |
Debt / Equity Ratio | 2.86 | 6.80 | 2.02 | 9.51 | 0.87 | 1.16 |
Quick Ratio | 2.70 | 2.04 | 3.41 | 3.39 | 4.64 | 4.35 |
Current Ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 | 4.43 |
Asset Turnover | 0.81 | 0.39 | 0.18 | 0.16 | 0.17 | 0.33 |
Interest Coverage | -5.85 | -28.96 | -34.25 | -29.04 | -10.13 | -9.25 |
Return on Equity | -22.25% | -544.28% | -55.47% | -649.88% | -59.61% | -80.22% |
Return on Assets | -4.22% | -54.12% | -14.12% | -41.40% | -23.19% | -27.89% |
Return on Invested Capital | -13.95% | -69.27% | -63.02% | -59.79% | -30.38% | -30.69% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% | 96.91% |
Net Profit Margin | -5.21% | -137.90% | -76.70% | -254.41% | -136.60% | -85.43% |
Pretax Profit Margin | -10.04% | -137.45% | -258.96% | -302.54% | -164.51% | -95.19% |
Operating Profit Margin | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% | -88.83% |
FCF Margin | -4.15% | -145.25% | -221.44% | -196.11% | -29.54% | -81.98% |
EBITDA Margin | 4.53% | -113.98% | -224.63% | -273.54% | -139.91% | -73.19% |
Add to Watchlist
Select watchlists to add or remove TVTX